Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elliot Cazes

Obstetrics & Gynecology Tampa, FL Medical Doctor

NPI 1629042460 CMS profile 1305901

14424 Bruce B Downs Blvd, Tampa, FL 33613

Open in the dashboard

General payments

$725,157

954 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$101,781 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Elliot Cazes of Tampa, FL is reported in the CMS Open Payments database as having received $725,157 across 954 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $101,781 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $109,450 106
2024 General $119,670 102
2023 General $127,888 161
2022 General $115,599 201
2021 General $151,243 235
2020 General $75,391 97
2019 General $25,918 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elliot Cazes
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Elliot Cazes were reported at $109,450. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Elliot Cazes Obstetrics & Gynecology median Middle half National median
2019 $25,918 $172 $62–$391 $163
2020 $75,391 $94 $36–$222 $114
2021 $151,243 $136 $42–$369 $132
2022 $115,599 $160 $50–$433 $149
2023 $127,888 $169 $56–$423 $160
2024 $119,670 $152 $50–$371 $164
2025 $109,450 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mayne Pharma Inc. $293,453 259 payments
  2. AbbVie, Inc. $240,299 325 payments
  3. Myovant Sciences Inc. $104,892 196 payments
  4. Sumitomo Pharma America, Inc. $45,120 94 payments
  5. ASCEND Therapeutics US, LLC $23,016 15 payments
  6. Pfizer Inc. $14,122 15 payments
  7. SCYNEXIS, Inc. $3,590 15 payments
  8. Astellas Pharma US Inc $230 6 payments
  9. TherapeuticsMD, Inc. $112 9 payments
  10. Roche Diagnostics Corporation $60 4 payments
  11. Other $263 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $574,897 217 payments
  2. Travel and Lodging $76,649 296 payments
  3. Food and Beverage $32,145 414 payments
  4. Honoraria $26,755 8 payments
  5. Consulting Fee $14,400 6 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $173 1 payment
  7. Education $136 4 payments
  8. Gift $3 8 payments
Products named General payments · program years 2019–2025
  1. MYFEMBREE $147,943 284 payments
  2. ORIAHNN $147,207 182 payments
  3. NEXTSTELLIS Contraceptive $125,393 102 payments
  4. ORILISSA Womens Health $75,982 102 payments
  5. ANNOVERA Contraceptive $63,906 49 payments
  6. ANNOVERA Contraception $56,534 53 payments
  7. BIJUVA $41,343 39 payments
  8. NEXTSTELLIS Contraception $34,644 35 payments
  9. Orilissa Endocrinology $25,829 46 payments
  10. ESTROGEL $23,016 15 payments
  11. Other $7,073 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

39

Median for Obstetrics & Gynecology: 65

Drug cost

$5,137

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

69.2%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Bijuva Estradiol/Progesterone Brand 15 $3,919
Estradiol Generic 12 $940
Progesterone Progesterone, Micronized Brand 12 $278

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NEXTSTELLIS
$42,670 — —
ESTROGEL
$13,003 — —
Veozah
$56 — —
MYFEMBREE
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

954 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record